Clinical Trials

Text Size A A

E-Mail to a Friend

secret  Click to Play Audio

Gastrointestinal Cancer


Regorafenib for Gastrointestinal Stromal Tumors (7390)
A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib

Investigator: Robin Jones;   Conditions: Gastrointestinal Cancer;    Status: Closed;   Study ID: NCT01271712